Publications by authors named "Peter Farrehi"

Article Synopsis
  • The study aimed to assess the effectiveness and safety of low (81 mg) versus high-dose (325 mg) aspirin in patients with established atherosclerotic cardiovascular disease (ASCVD) across different racial groups.
  • Conducted as a secondary analysis of the ADAPTABLE trial, the research involved over 14,000 participants from various racial backgrounds and compared their responses to different aspirin doses over a median follow-up of 26.2 months.
  • The results indicated that race did not significantly alter the effectiveness or safety of aspirin dosing, suggesting that all racial groups responded similarly to the treatment.
View Article and Find Full Text PDF
Article Synopsis
  • - Atherosclerotic cardiovascular disease (ASCVD) is the main health issue in the US, and while aspirin is commonly used for its prevention, a trial (ADAPTABLE) found no significant difference in outcomes between 81 mg and 325 mg doses of aspirin.
  • - The study aimed to investigate whether there are differences in safety and effectiveness of the two aspirin doses based on sex, as previous findings didn't address this.
  • - Conducted across multiple medical centers, the ADAPTABLE trial involved over 15,000 participants with established ASCVD, analyzing outcomes related to major bleeding, heart attacks, and strokes, with a focus on comparing male and female responses to the aspirin doses.
View Article and Find Full Text PDF
Article Synopsis
  • In patients with atherosclerotic cardiovascular disease, increased age is linked to higher risks of both ischemic and bleeding events, prompting a study on the effect of aspirin dosage based on age.
  • The ADAPTABLE trial involved nearly 15,100 participants who were randomly assigned to take either 81 mg or 325 mg of aspirin daily, with outcomes measured over an average follow-up of 26.2 months.
  • Results indicated that age did not significantly affect how aspirin dosage influenced clinical outcomes, suggesting that both doses are similarly effective for elderly and younger patients in preventing cardiovascular events.
View Article and Find Full Text PDF
Article Synopsis
  • The ADAPTABLE trial, a large study on aspirin dosing for preventing heart issues, showed no significant difference in efficacy between high- and low-dose aspirin in patients with cardiovascular disease.
  • It explored whether using P2Y12 inhibitors like clopidogrel or prasugrel impacted aspirin's effectiveness or safety; however, results indicated no interaction between aspirin dose and P2Y12 inhibitor use.
  • Participants taking P2Y12 inhibitors had a higher risk of major cardiovascular events but not an increased risk of bleeding, and switching doses was more common in the high-dose group without being influenced by P2Y12 inhibitor status.
View Article and Find Full Text PDF
Article Synopsis
  • Clinicians recommend enteric-coated aspirin to reduce gastrointestinal bleeding for patients with coronary artery disease, despite evidence suggesting it may be less effective at inhibiting platelets than uncoated aspirin.
  • This study analyzed data from the ADAPTABLE trial, which involved over 15,000 patients with atherosclerotic cardiovascular disease, to compare the effectiveness and safety of enteric-coated versus uncoated aspirin.
  • The primary outcomes measured were the occurrence of major cardiovascular events and major bleeding incidents, with findings indicating the differences in these outcomes between the two aspirin formulations over approximately 26 months of follow-up.
View Article and Find Full Text PDF
Article Synopsis
  • Patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) were studied to determine the impact of different aspirin doses on cardiovascular risks and bleeding events.* -
  • The research involved 15,076 patients, revealing that those with DM had higher rates of cardiovascular issues and bleeding compared to those without DM, regardless of whether they took 81 mg or 325 mg of aspirin.* -
  • The results indicate that increasing the dose of aspirin does not provide additional benefits for patients with DM, highlighting their increased risk in general rather than a response to medication.*
View Article and Find Full Text PDF
Article Synopsis
  • - The ADAPTABLE trial examined the effects of different doses of aspirin (81 mg vs 325 mg daily) on cardiovascular events and bleeding rates in patients with existing cardiovascular disease, finding no significant differences between the two doses.
  • - In a secondary analysis focusing on patients with chronic kidney disease (CKD), results showed that CKD patients had a higher risk of adverse cardiovascular outcomes and major bleeding, regardless of the aspirin dose they were taking.
  • - The study concluded that while CKD increased the risk for complications, the dosing of aspirin did not affect the risk of adverse events or bleeding in these patients.
View Article and Find Full Text PDF

The brain is assumed to be hypoactive during cardiac arrest. However, animal models of cardiac and respiratory arrest demonstrate a surge of gamma oscillations and functional connectivity. To investigate whether these preclinical findings translate to humans, we analyzed electroencephalogram and electrocardiogram signals in four comatose dying patients before and after the withdrawal of ventilatory support.

View Article and Find Full Text PDF

Objective: To determine if oral hygiene is associated with infective endocarditis (IE) among those at moderate risk for IE.

Study Design: This is a case control study of oral hygiene among hospitalized patients with IE (cases) and outpatients with heart valve disease but without IE (controls). The primary outcome was the mean dental calculus index.

View Article and Find Full Text PDF

Background/aims: Actively engaging patient partners in the conduct of trials is crucial to ensure the studies answer genuine, patient-centered, unmet clinical needs, and to facilitate participant recruitment and retention. The aim of this article is to demonstrate the feasibility of patient engagement within a large pragmatic multicenter randomized controlled trial, specifically for the purposes of dissemination of study information/updates and to favorize recruitment and retention.

Methods: In the patient-centric, pragmatic ADAPTABLE randomized trial, transparent and timely dissemination of information on the study updates to the trial participants was undertaken to create meaningful engagement and to facilitate retention.

View Article and Find Full Text PDF

Background: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.

Methods: Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis.

View Article and Find Full Text PDF

Importance: Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question.

Objective: To report the rationale and design for a randomized clinical trial to determine the optimal dosage of aspirin to be used for secondary prevention of ASCVD, using an innovative research method.

Design, Setting, And Participants: This pragmatic, open-label, patient-centered, randomized clinical trial is being conducted in 15 000 patients within the National Patient-Centered Clinical Research Network (PCORnet), a distributed research network of partners including clinical research networks, health plan research networks, and patient-powered research networks across the United States.

View Article and Find Full Text PDF

Background and Purpose- Cardiac telemetry is a routine part of inpatient ischemic stroke/transient ischemic attack evaluation to assess for atrial fibrillation (AF). Yet, tools to assist stroke clinicians in the evaluation of the large quantities of telemetry data are limited. The investigators developed a new method to evaluate electrocardiographic signals, electrocardiomatrix, that was applied to stroke unit telemetry data to determine its feasibility, validity, and usefulness.

View Article and Find Full Text PDF

Sudden death is an important but underrecognized consequence of stroke. Acute stroke can disturb central control of autonomic function and result in cardiac dysfunction and sudden death. Previous study showed that bilateral common carotid artery ligation (BCCAL) in the spontaneously hypertensive stroke-prone rat strain (SHRSP) is a well-established model for forebrain ischemic sudden death.

View Article and Find Full Text PDF

Obstructive sleep apnea (OSA) commonly coexists with the metabolic syndrome, a condition for which behavioral changes are often prescribed. Whether OSA diminishes the cardiometabolic health benefits from lifestyle interventions remains unclear. We evaluated 278 consecutive metabolic syndrome participants enrolled in a 12-week comprehensive lifestyle intervention program.

View Article and Find Full Text PDF

Background: Atrial fibrillation (AFIB) and atrial flutter (AFL) are two common cardiac arrhythmias that predispose patients to serious medical conditions. There is a need to accurately detect these arrhythmias to prevent diseases and reduce mortality. Apart from accurately detecting these arrhythmias, it is also important to distinguish between AFIB and AFL due to differing clinical treatments.

View Article and Find Full Text PDF

Sudden cardiac arrest is a leading cause of death in the United States. The neurophysiological mechanism underlying sudden death is not well understood. Previously we have shown that the brain is highly stimulated in dying animals and that asphyxia-induced death could be delayed by blocking the intact brain-heart neuronal connection.

View Article and Find Full Text PDF

Background: Patients are commonly provided tools in the hospital to overcome poor sleep. Whether education on use of sleep tools can impact health outcomes from a patient perspective is not known.

Methods: We recruited 120 adults admitted to a nonintensive care unit cardiac-monitored floor.

View Article and Find Full Text PDF

Background: Recurrent atrial fibrillation (AF) after successful cardioversion can be predicted by obstructive sleep apnea (OSA) diagnosed by polysomnography. However, it is not known whether the validated STOP-BANG questionnaire can predict AF recurrence after radiofrequency ablation (RFA). Our objective is to determine the prevalence of unrecognized OSA in patients with AF and its relation to freedom from AF after RFA.

View Article and Find Full Text PDF

Objective: To determine factors contributing to the relatively high frequency and variability (10% to 30%) of finding no significant coronary disease by coronary angiography in patients with chest pain.

Study Design: Retrospective, comparative analysis of practice patterns at 3 southeastern Michigan hospitals and a composite sample from New York State.

Patients And Methods: Medical records for 7668 patients were reviewed to determine the frequency of negative coronary arteriographic findings in patients undergoing chest pain evaluation.

View Article and Find Full Text PDF